

Epidemiology of HIV and viral hepatitis, and harm reduction response In South East Europe



Data from the *Global State of Harm Reduction 2020*
Produced by the [Harm Reduction International](#)*

Country/ territory with reported injecting drug use	People who inject drugs	HIV prevalence among people who inject drugs (%)	Hepatitis C (anti- HCV) prevalence among people who inject drugs (%)	Hepatitis B (anti- HBsAg) prevalence among people who inject drugs (%)	Harm reduction response			
					Needle and syringe programme (NSP)	Opioid agonist therapy (OAT)**	Peer distribution of naloxone	Drug consumption rooms (DCRs)
Albania	5,132 - 6,182	0.5	28.8	11.5	✓ 2	✓ 6 (M, B)	✗	✗
Bosnia Herzegovina	12,500	0.0	30.8	0.2 - 3.1	✓ 5	✓ 12 (M,O)	✗	✗
Bulgaria	18,500	6	76.8	5.0	✗	✓ 30 (M,B,O)	✗	✗
Croatia	6,300	0.5	38.2	0.9	✓ 144	✓ (M,B,O)	✗	✗
Greece	3,339	4.1	60.5	2.2	✓ 12	✓ (B,M)	✗	✗
Kosovo*	5,819	0.0	23.8	4.1	✓	✓ 4 (M)	✗	✗
Montenegro	1,300	0.5	53.0	1.4	✓ 13	✓ 5	✗	✗
North Macedonia	6,756	0.0	72	5.6	✓ 16	✓ 16 (M,B)	✗	✗
Romania	81,500	15.9	83.8	5.2	✓ 63	✓ (M)	✗	✗
Serbia	20,500	0.0	25.9	3.6	✓ 2	✓ 23 (M,B)	✗	✗
Slovenia	4,900	0.0	42.6	4.6	✓ 12	✓ 10 (M,B,O)	✗	✗
Turkey	12,733	0.5	49.2	3.5	✗	✓ (B,M,O)	✗	✗

* References for the data are available in the original document

** Methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine